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ABSTRACT
High-grade gliomas (HGGs) are very aggressive brain tumors with a cancer 
stem cell component. Cells, including cancer stem cells, release vesicles called 
exosomes which contain small non-coding RNAs such as microRNAs (miRNAs). 
These are thought to play an important role in cell-cell communication. However, we 
have limited knowledge of the types of exosomal miRNAs released by pediatric HGG 
stem cells; a prerequisite for exploring their potential roles in HGG biology. Here we 
isolated exosomes released by pediatric glioma stem cells (GSCs) and compared their 
repertoire of miRNAs to genetically normal neural stem cells (NSCs) exosomes, as 
well as their respective cellular miRNA content. Whereas cellular miRNAs are similar, 
we find that the exosomal miRNA profiles differ between normal and tumor cells, 
and identify several differentially expressed miRNAs. Of particular interest is miR-
1290 and miR-1246, which have previously been linked to ‘stemness’ and invasion 
in other cancers. We demonstrate that GSC-secreted exosomes influence the gene 
expression of receiving NSCs, particularly targeting genes with a role in cell fate and 
tumorigenesis. Thus, our study shows that GSCs and NSCs have similar cellular miRNA 
profiles, yet differ significantly in the repertoire of exosomal miRNAs and these could 
influence malignant features of HGG.
INTRODUCTION
Pediatric high grade gliomas (HGGs) are one of the 
most significant causes of morbidity and mortality among 
children due to their aggressive clinical behavior [1]. One 
of the driving forces behind the growth of HGG is thought 
to be a subpopulation of glioma stem cells (GSCs) [2]. 
The generation and maintenance of these tumorigenic cells 
is orchestrated in part by transcriptional and epigenetic 
changes [3], such as those induced by microRNAs 
(miRNAs).
MiRNAs are small non-coding RNAs (19-25 
nucleotides long) and function as mRNA silencers and 
transcriptional regulators of gene expression. They 
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have been identified to have important roles in tumor 
development and progression as oncomirs [3–5]. MiRNAs 
are also present in small (30-100 nm) sized membrane 
vesicles called exosomes [6, 7] which have an endocytic 
origin and are released by different cell types [8]. 
Exosomes have gained much attention since the discovery 
of their RNA content and the important role they have in 
cell to cell communication [9] as well as their possible role 
in tumor progression [10]. Previous studies have described 
miRNA expression in pediatric brain tumors [11, 12], 
differences between pediatric and adult gliomas [13], 
and in exosomes derived from adult glioblastoma (GBM) 
cell lines [14, 15]. However, nothing is known about the 
expression pattern of exosomal miRNAs, secreted by 
primary cell cultures originating from pediatric HGG 
patients. This is essential if we are to understand any 
potential role they have in the biology of HGG.
Here we used primary patient-derived GSCs to 
survey the expression of a large number of miRNAs – 
both exosome derived and cellular – in pediatric GSCs 
and compared these to normal neural fetal stem cells 
(NSCs) reference controls. We find that exosomes from 
GSCs altered the gene expression of recipient NSCs, 
suggesting that the exosomes could have a role in the 
tumor microenvironment influencing the properties of 
neighboring cells.
RESULTS
Characterization of exosomes released by glioma 
stem cells and neural stem cells
We used NSCs and patient-derived primary cell 
cultures from pediatric HGG (GSCs) grown in stem cell 
conditions. The GSCs have previously been thoroughly 
described [16]. Briefly, the cells express stem cell 
proteins, respond to differentiation cues and are tumor-
initiating when orthotopically injected into mouse brains. 
The NSCs also express stem cell markers and have the 
capacity to differentiate (Supplementary Figure 1 and 
[17]). Extracellular vesicles released by the cells were 
isolated from the cell culture media (see Material and 
Methods). We characterized the exosomes based on 
their size and morphology using Transmission Electron 
Microscopy and Nanoparticle Tracking Analysis. The 
analyses confirmed the typical exosome shape and size 
(Figure 1A–1B) [18]. Presence of the exosomal surface 
Figure 1: Characterization of exosomes isolated from neural and brain tumor stem cells. (A) Representative image from 
transmission electron microscopy of exosomes (Exo) (for each sample group), scale bars: 200 nm. (B) Determination of exosome size 
distribution by Nanoparticle Tracking Analysis and (C) characterization with Western blot of exosomal surface markers CD9 and CD81, 
and cell-specific marker Calnexin in cells and exosomes.
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markers CD81 and CD9 was indicated by Western blot. 
By contrast, Calnexin, an endoplasmic reticulum marker 
only present in cells, was absent (Figure 1C) [18].
The miRNA expression pattern differs in cells 
and exosomes
We analyzed miRNA expression in cells and 
exosomes from six GSC and three NSC lines and detected, 
in total, 1954 miRNAs. Among these, 250 miRNAs were 
present in both sets of samples (in both cells and exosomes); 
480 were present in all cell samples; 389 were detected 
in all of the exosome samples. The detected miRNAs in 
exosomes (exosomal miRNAs) clustered separately from 
those in cells (cellular miRNAs) based on their expression 
level (intensity) (Figure 2A). We detected 334 miRNAs that 
were present only in cells (cell-specific miRNAs) and 355 
miRNAs that were present only in exosomes (exosome-
specific miRNAs). Hence, both the quantity and nature of 
the miRNAs differed between cells and exosomes based on 
expression levels and the type of miRNA expressed.
Identification of differentially expressed miRNAs
We next focused on those miRNAs differentially 
expressed in the GSCs and NSCs. We detected 10 
upregulated and 14 down-regulated miRNAs in the GSCs 
compared to the NSCs (Table 1, p<0.05). Reassuringly, 
the top up-regulated candidate was the glioma-associated 
miRNA-497-5p [19].
We detected a larger number of differentially 
expressed miRNAs in the exosomes than in the cells; 
37 miRNAs were up-regulated and five down-regulated 
in the GSC exosomes compared to the NSC exosomes 
(Table 2, p<0.05). Several of the upregulated miRNAs 
have not been identified previously in the context of GSC 
exosomes, such as miR-1290, miR-1246, miR-4299, 
miR-4732-5p, miR-6830-5p and miR-6165. We also 
detected many upregulated miRNAs that previously have 
been described to have a role in brain tumors such as 
miR-30c-1-3p [20], let-7a-5p [21], miR-24-3p [22] and 
miR-494-3p [23]. MiRNAs downregulated in the GSC 
exosomes included miR-4690-5p, miR-4443 and miR-
198. We used qPCR to validate the miRNA array data, 
which confirmed the obtained results (Supplementary 
Figure 2). Enriched KEGG pathways targeted by the 
miRNAs that were differentially expressed between 
GSC and NSC exosomes included several cancer-related 
signaling pathways, such as Choline metabolism in 
cancer, Proteoglycans in cancer and Glioma (Figure 2B).
In summary, we detected disease-associated pathways 
in the relevant miRNA expression differences between 
exosomes from GSCs and NSCs. Also, the exosome 
samples displayed a larger number of differentially 
expressed miRNAs between GSC and NSC than the cell 
samples, suggesting a specific active mechanism that is 
sorting miRNAs into exosomes and an important role of 
these vesicles in cell to cell communication.
Identification of differentially expressed miRNAs 
in exosomes compared to cells suggest a potential 
role of the exosomal miRNAs
Next, we compared the miRNA expression of the 
exosomes to the expression in their originating cells and 
Figure 2: miRNA distribution and targeted pathways. (A) Hierarchical clustering with Euclidean distance of log2 miRNA 
expression in all samples. Undetected miRNAs are colored grey. The exosomes and cells cluster separately based on their miRNA intensity. 
(B) Top 15 targeted KEGG pathways of the differentially expressed miRNAs between Glioma stem cell (GSC) exosomes and normal neural 
stem cell (NSC) exosomes include several relevant cancer pathways.
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detected 152 differentially expressed miRNAs between 
NSCs and their exosomes, and 196 differentially expressed 
miRNAs between GSCs and their exosomes. Most of these 
miRNAs were up-regulated in the exosomes (NSCs: 100, 
GSCs: 147) (Supplementary Tables 1-2).
To determine why some of the miRNAs had higher 
intensities in the exosomes compared to their originating 
cells, we searched for motifs in their sequence. We 
detected two often repeating patterns (Figure 3A) in the 
miRNAs from the GSC and NSC exosomes. One of the 
sequence patterns, GGAG, has previously been described 
[24] and termed ‘exo motif’ and the second motif was 
GGGGC. Figure 3B displays miRNAs overexpressed in 
GSC or NSC exosomes compared to their cell counterparts 
and that contains one or both of the identified motifs.
Furthermore, we identified miRNAs that were 
differentially expressed between GSC exosomes and cells 
but not differentially expressed in NSC exosomes compared 
to their originating cells. This group of miRNAs, ‘glioma 
exosome specific’, was composed of 92 miRNAs, most of 
them (71) being up-regulated in the exosomes compared to 
their originating cells, for example miR-4467, miR-638 and 
miR-6727-5p (Figure 3C, Supplementary Table 3). In order 
to gain more information about the up-regulated ‘glioma 
exosome specific’ miRNAs, we searched for their targeted 
pathways using KEGG. Interestingly, most of the targeted 
Table 1: Differentially expressed microRNAs in GSCs compared to NSCs
miRNA FCa p-valueb BHc
Up-regulated    
miR-497-5p 11.76 2.70E-06 1.30E-03
miR-551b-3p 3.04 5.92E-03 5.91E-01
miR-195-5p 2.99 5.79E-03 5.91E-01
miR-9-3p 2.68 2.08E-02 7.70E-01
miR-101-3p 2.48 2.95E-02 8.27E-01
miR-505-5p 2.26 4.90E-02 8.27E-01
miR-1199-5p 2.15 3.96E-02 8.27E-01
miR-487a-3p 2.09 2.67E-02 8.27E-01
miR-4783-5p 2.05 4.85E-02 8.27E-01
miR-187-5p 2.02 4.87E-02 8.27E-01
Down-regulated    
miR-29a-3p 2.20 4.77E-02 8.27E-01
miR-665 2.33 4.31E-02 8.27E-01
miR-4327 2.35 3.20E-02 8.27E-01
miR-3180 2.46 3.96E-02 8.27E-01
miR-4476 2.66 3.70E-02 8.27E-01
miR-3620-5p 2.59 1.72E-02 7.40E-01
miR-4688 2.72 1.85E-02 7.40E-01
miR-221-3p 5.61 1.84E-02 7.40E-01
miR-335-5p 6.12 1.75E-02 7.40E-01
miR-3131 3.19 1.15E-02 6.90E-01
miR-6880-5p 2.54 7.60E-03 5.91E-01
miR-4690-5p 2.82 8.63E-03 5.91E-01
miR-4486 3.08 6.88E-03 5.91E-01
miR-8089 3.86 4.23E-03 5.91E-01
aFC-Fold change, b p-value <0.05 and c BH- Benjamini-Hochberg adjusted p-value.
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Table 2: Differentially expressed microRNAs in GSC exosomes compared to NSC exosomes
miRNA FCa p-valueb BHc
Up-regulated    
miR-4299 5.52 8.87E-05 1.38E-02
miR-4732-5p 5.49 9.23E-05 1.38E-02
miR-6830-5p 5.41 1.07E-04 1.38E-02
miR-7975 4.91 2.61E-04 2.34E-02
miR-1290 4.83 3.00E-04 2.34E-02
miR-1246 4.66 4.08E-04 2.65E-02
miR-3126-5p 4.34 7.49E-04 4.16E-02
miR-6715b-5p 4.27 8.64E-04 4.20E-02
miR-1273g-3p 4.09 1.22E-03 4.70E-02
miR-8078 4.02 1.39E-03 4.70E-02
miR-4428 4.02 1.40E-03 4.70E-02
miR-6165 3.89 1.81E-03 4.70E-02
miR-4454 3.75 2.40E-03 5.81E-02
miR-5100 3.70 2.65E-03 5.81E-02
miR-30c-1-3p 3.70 2.69E-03 5.81E-02
miR-652-5p 3.56 3.54E-03 7.25E-02
miR-4531 3.52 3.82E-03 7.43E-02
miR-513b-5p 3.30 6.06E-03 1.07E-01
miR-6778-5p 3.29 6.19E-03 1.07E-01
miR-6851-5p 3.28 6.31E-03 1.07E-01
miR-513a-5p 3.19 7.68E-03 1.24E-01
miR-4286 3.16 8.19E-03 1.27E-01
let-7a-5p 2.98 1.21E-02 1.74E-01
miR-5006-5p 2.96 1.27E-02 1.77E-01
miR-3162-5p 2.90 1.43E-02 1.86E-01
miR-4753-5p 2.89 1.47E-02 1.86E-01
miR-711 2.88 1.51E-02 1.86E-01
miR-665 2.87 1.53E-02 1.86E-01
miR-24-3p 2.83 1.69E-02 1.96E-01
miR-3714 2.82 1.72E-02 1.96E-01
miR-3122 2.75 2.00E-02 2.22E-01
miR-4649-5p 2.61 2.78E-02 3.01E-01
miR-6893-5p 2.57 3.03E-02 3.10E-01
miR-6870-5p 2.56 3.09E-02 3.10E-01
miR-7977 2.55 3.17E-02 3.10E-01
miR-494-3p 2.54 3.25E-02 3.10E-01
miR-4688 2.38 4.66E-02 4.32E-01
Down-regulated    
miR-4690-5p 3.91 1.75E-03 4.70E-02
miR-4443 3.91 1.74E-03 4.70E-02
miR-198 3.94 1.63E-03 4.70E-02
miR-3180 2.99 1.20E-02 1.74E-01
miR-6840-3p 2.53 3.27E-02 3.10E-01
aFC-Fold change, b p-value <0.05 and c BH- Benjamini-Hochberg adjusted p-value.
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Figure 3: Exosomal miRNAs and their specific motifs. (A) The two frequently present motifs in miRNAs overexpressed in Glioma 
stem cells (GSC) exosomes compared to GSCs and in normal neural stem cell (NSC) exosomes compared to NSCs. (B) miRNAs overexpressed 
in NSC exosomes compared to NSCs (left) and miRNAs overexpressed in GSC exosomes compared to GSCs (right) whose sequences contain 
GGAG (green), GGGGC (red) or both GGAG and GGGGC (purple). (C) Top 10 ‘glioma exosome specific’ miRNAs: these miRNAs have 
significant differential expression in the GSC exosomes compared to their cells while there is no significant differential expression in NSC 
exosomes compared to their originating cells and (D) the top 15 targeted KEGG pathways by the ‘glioma exosome specific’ miRNAs.
pathways were cancer-, signaling- and glioma-related 
(Figure 3D). Based on these results, we hypothesize that 
loading of exosomal miRNAs are not random, but rather an 
effect of a well-defined mechanism.
Exosomes from glioma stem cells alter the gene 
expression of recipient cells
To determine if there is any potential functional 
role of exosomes secreted by GSCs, we aimed to test 
if the exosomes could affect normal recipient cells. We 
first verified, by confocal imaging, that exosomes can be 
taken up by NSCs (Supplementary Figure 3). Thereafter 
we treated cells with as follows, prior to gene expression 
analysis on TaqMan Low Density Array (TLDA) cards: 
1) exosomes isolated from GSC (GU-pBT-28) media; 
2) exosomes previously isolated from NSCs; and 3) no 
exosome treatment (Figure 4A). We profiled 192 genes 
that were predicted/validated target genes of the up-
regulated GSC exosomal miRNAs or had a role in cell 
cycle, stemness, differentiation, glioma genesis, and 
neurogenesis.
We detected several gene expression changes 
induced by the GSC exosomes that were not induced by 
the NSC exosomes (Figure 4B). In total, 27 genes showed 
significant differential expression; 23 genes were down-
regulated and four genes up-regulated (Figure 4C) in 
response to the GSC exosome treatment. Additionally, 
two up-regulated genes, LMX1B and GPR37L1, were 
also up-regulated in response to the treatment with NSC 
exosomes. Down-regulated transcripts included the tumor 
suppressor gene PTEN [25], stemness/differentiation/cell 
fate genes such as NOTCH1, NOTCH2, JAG1, DLL1, 
GFAP, and the cell cycle-related genes RAD9A, MCM5 
and RBL2 (Figure 4C). The majority (19 of 23) of these 
down-regulated genes is predicted or validated mRNA 
targets for several of the up-regulated GSC exosomal 
miRNAs, which could indicate a direct effect (Figure 4D). 
For example, the GBM tumor suppressor gene TET3 [26] 
is likely downregulated by the delivered exosomal miR-
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24-3p, known to be up-regulated in brain tumors [22] and 
validated to target TET3 (Tarbase).
Up-regulated genes included the glioma related 
genes SEC61G and LNX1 and the cell cycle related 
SERTAD1 and CCNH (Figure 4C). The upregulation could 
be due to an indirect effect from the exosomal miRNAs 
or result from the mRNA content of the GSC exosomes.
Further, we examined which biological processes 
the altered genes are involved in and found relevant 
enriched GO terms such as nervous system development, 
neurogenesis or neuron differentiation (the genes 
measured by the TLDA cards was used as background for 
the enrichment analysis) (Figure 4E). In conclusion, these 
data suggest that GSC exosomal miRNAs altered the gene 
expression of the receiving NSCs in a manner that could 
affect several biological processes.
DISCUSSION
Previous studies have catalogued the miRNA 
expression profiles of pediatric GBM tumors [12, 13]. 
However, for a better understanding of these tumors’ 
biology it is crucial to study the cancer stem cells which 
have an important role in cancer development, progression 
and recurrence [2]. These cancer stem cells are thought 
to be regulated by several epigenetic mechanisms, with 
miRNAs being one of them [3]. MiRNAs are present 
in exosomes, vesicles that play an important role in cell 
communication. Hence, we here determined miRNA 
profiles of pediatric HGG-derived cancer stem cells and 
their exosomes. We further investigated their effect on 
NSCs.
We detected few differentially expressed cellular 
miRNAs between the GSCs and the NSCs, but a larger 
number in the exosome samples. These miRNAs are 
validated or predicted to be involved in relevant signaling 
pathways suggesting that they could have a role in 
the tumorigenic process. The loading of the miRNAs 
with a higher expression in exosomes compared to the 
cells therefore does not seem to be random, but rather 
suggestive of an active mechanism of sorting/loading, at 
least partly based on the recognition of different miRNA 
motifs that are favored for loading into the exosomes [24]. 
The specific mechanisms underlying this observation 
require further investigation.
Figure 4: GSC exosomes effect on NSC gene expression. (A) Experimental set-up. (B) Hierarchical clustering of log2 intensities 
of genes measured by the TLDA cards in the three different experimental conditions, displaying a different profile of the GSC exosome 
treated cells. (C) Gene expression in NSC after GSC exosome treatment, where fold change (FC) less than the blue line or above the red line 
was defined as differentially expressed (Methods). (D) Up-regulated GSC exosomal miRNAs (orange) and their target (validated, Tarbase, 
arrow in black and predicted, microT-CDS, arrow in red) mRNAs (green) that were downregulated in NSC after GSC exosomal treatment 
and (E) top 10 biological processes affected by the differentially expressed genes in the GSC exosome treated NSCs.
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We identified several exosomal miRNA which 
have previously been reported to have a role in cancer 
and stemness [27]. These included two evolutionary 
young miRNAs, miR-1246 and miR-1290, that have 
been described to have a role in neuronal differentiation 
[28]. The secretion of these miRNAs through exosomes 
could potentially be a result of the GSCs attempting to 
maintain their stemness by eliminating factors that induce 
differentiation. Alternatively, as the same miRNAs have 
been associated with cancer cell proliferation, stemness, 
invasion and chemoresistance in several tumor forms 
[29–33], one could speculate that the tumor cells mediate 
tumorigenic signals to cells in their microenvironment 
through the exosomes. We therefore investigated the 
potential of the exosomes to alter recipient cells, by 
profiling gene expression changes in NSCs resulting 
from GSC exosome treatment, and detected down-
regulated expression of glioma-associated tumor 
suppressors PTEN [34] and TET3 [26]. Apart from 
inducing down-regulation of genes, the GSC exosomes 
also induced up-regulation of cancer-related genes such 
as SERTAD1 and SEC61G [35–37] which would support 
the hypothesis that exosomes released by tumor cells can 
promote tumorigenesis. These changes were not a direct 
effect of the up-regulated GSC exosomal miRNAs, but 
rather an indirect effect of the miRNAs or explained 
by other material in the exosomes. One limitation of 
our study is the relatively limited number of samples 
included. However pediatric cancer stem cells are not 
easily obtained and our unique cultures represent one of 
very few collections of well-characterized cells that are 
currently available [16]. Future studies will be needed 
to extend the broader significance of our observations. 
Moreover the specific contribution of each miRNA 
identified here remains to be explored.
In conclusion, the present study describes the 
miRNA expression pattern in pediatric HGG-derived stem 
cells and in the exosomes derived therefrom, as well as 
their potential role in affecting recipient cells. The study 
provides new insights into epigenetic regulation of cancer 
stem cells from pediatric brain tumors, as well as the 
possible roles of the exosomes in the regulation of normal 
cells in their microenvironment. These findings may act 
as a basis for further studies towards better diagnostics 
or prognostic biomarker development, as well as for 
deciphering the specific role of exosomes in cancer stem 
cell maintenance, regulation and progression.
MATERIALS AND METHODS
Patients and samples
The study was approved by the regional ethics 
committee (Dnr 604-12). Tumor samples were obtained 
after signed informed consent from the parents of children 
who underwent surgery at the Sahlgrenska University 
Hospital, Gothenburg, Sweden.
Cell cultures and exosome isolation
Established patient-derived primary cell cultures 
were grown in stem cell media (DMEM-F12 supplemented 
with B27 (Gibco), N2 (Gibco), EGF (20 ng/ml, Peprotech) 
and in some cases FGF-2 (20 ng/ml) on laminin (Sigma)-
coated plastics as previously described [38]. Fresh media 
was added every 4 day. All established cell cultures were 
confirmed negative for mycoplasma contamination. The 
following cell lines were used: normal neural stem cells 
(NSCs): NS-1, NS-4, NS-5 and pediatric glioma stem 
cells (GSC): GU-pBT-7, GU-pBT-10, GU-pBT-15, GU-
pBT-19, GU-pBT-23 and GU-pBT-28. The GSC lines are 
the same as in Wenger et al [16], described under different 
names, as follows: BPC-A7, BPC-B0, BPC-B5, BPC-B9, 
BPC-C3 and BPC-C8.
Conditioned medium was collected from each 
cell line and exosomes were purified by differential 
centrifugation [18]. In brief, the medium was centrifuged 
for 10 min at 300g to eliminate cell contamination. 
Supernatants were further centrifuged for 10 min at 
2000g to eliminate apoptotic bodies, followed by 
ultracentrifugation with Ti70 fixed-angel rotor (Optima 
L-90 K Beckman Coulter). The supernatant was 
centrifuged at 28000x g (19400 rpm) in order to pellet 
microvesicles, followed by filtration of the supernatant 
through a 0.22 μm filter. Exosomes were pelleted by 
ultracentrifugation at 118000x g (40000 rpm) for 120 min. 
The exosome pellets were re-suspended in PBS.
Exosome characterization
Western blot
For Western blot analysis, proteins were extracted 
from isolated exosomes with Radio-Immunoprecipitation 
Assay (RIPA) Buffer (Sigma-Aldrich) and volumes, 
corresponding to 20 μg of proteins, were separated on 10% 
a SDS-PAGE gel. Samples were then transferred onto a 
nitrocellulose membrane (Bio-Rad laboratories, Hercules, 
CA, USA), which was subsequently blocked in 5% Non-
Fat Dry Milk (Bio-Rad Laboratories). The membrane 
was incubated with primary antibodies against Calnexin 
(1:1000; clone H-70; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), CD9 (1:1000, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and CD81 (1:800; clone H-121; 
Santa Cruz Biotechnology, CA, USA) overnight at 4°C. 
Secondary antibody was ECL anti-rabbit IgG horseradish 
peroxidase-linked F(ab’)2 fragment (donkey-anti rabbit, 
1:10000; GE Healthcare, UK). The membrane was 
visualized with ECL Prime Western Blotting Detection 
(GE Healthcare Life Sciences) and a VersaDoc 4000 MP 
(Bio-Rad Laboratories).
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Nanoparticle tracking analysis
Size determination of exosomes was assayed using 
Zeta View (a Nanoparticle Tracking Analysis device: 
Particle Matrix, Germany).
Transmission electron microscopy
Exosomes (10μg) re-suspended in PBS were 
loaded onto Formvar/Carbon-coated grids (Ted Pella 
Inc., Redding, CA, USA) fixed in 2.5% glutaraldehyde, 
contrasted in 2% uranyl acetate and visualized with LEO 
912AB Omega electron microscope (Carl Zeiss NTS, 
Jena, Germany) [39].
RNA isolation and microarray
Total RNA from exosomes and cells were extracted 
using QIAzol Lysis Reagent (Qiagen). Glycogen 
(Invitrogen) was added to increase the yield of RNA. 
Extracted RNA from cells was treated with TURBO 
DNase (Invitrogen) and enriched in small RNA fraction 
with RNA Clean & Concentrator™-5 (Zymo Research). 
RNA was quantified with Qubit RNA HS Assay Kit 
(Invitrogen).
MiRNA microarray analyses were carried out 
with 3D-Gene Human miRNA Oligo chip ver.21 (Toray 
Industries), which detects 2565 miRNA transcripts. The 
intensity of each miRNA was analyzed with the 3D-Gene 
Scanner 3000 (Toray) with auto gain, auto focus and 
auto analysis settings, according to the manufacturer’s 
instructions. The data normalization was performed 
on miRNA “spots” with background subtracted data. 
A normalization factor was calculated based on 25 
divided with the median of the signal intensity of all 
background normalized data. Normalized data for each 
probe set and sample was calculated by multiplying 
background subtracted data with the normalization factor. 
The microarray data was analyzed with GenEx analysis 
software (MultiD Analyses).
Quantitative real-time PCR (qRT-PCR)
The relative quantification of selected differentially 
expressed miRNAs was performed by qRT-PCR with 
the miRCURY LNA™ Universal RT microRNA PCR, 
Starter Kit with validated primer sets (Exiqon, Denmark) 
using ABI 7500 FAST Real-Time PCR System. Extracted 
total RNA from exosomes and small RNA enriched from 
cell samples were used for reverse transcription (20 ng) 
by adding UniSp6 RNA Spike-in template according to 
the manufacturer protocol. Since no stable endogenous 
control for exosomal miRNA exists, we used UniSp6 for 
normalization. ΔCt values were transformed to relative 
quantities and log2 calculation was applied in order to 
compare the qRT-PCR data with the microarray data. 
Pearson’s Correlation was calculated between the qRT-
PCR and microarray data for each sample group. All 
experiments were done in technical replicates.
Immunocytochemistry
NS-5 was stained with mouse monoclonal nestin, 
R&D MAB1259, 1:500; rabbit polyclonal SOX2, 
Abcam ab97959, 1:1000; mouse monoclonal GFAP, 
Sigma-Aldrich G3893 and incubated overnight at 4°C. 
When applicable, EdU was visualized according to the 
manufacturer’s instructions. Goat secondary antibody 
conjugated to Alexa dye, 1:1000 (Molecular Probes) 
was added for 1 h at room temperature and DAPI was 
used as a nuclear counterstain. Imaging of the cells was 
performed with the Operetta (Perkin Elmer). PKH67 
Green Fluorescent Cell Linker for General Cell Membrane 
Labelling (Sigma-Aldrich) staining was used for 
exosomes for the confocal imaging (LSM 700 Carl Zeiss 
microscope) of the exosome up-take by cells.
Functional study
Total RNA was isolated from NSCs treated 
daily for 8 days with 1) 30μg/ml exosomes from GSCs 
(GU-pBT-28), 2) NSC exosomes or 3) only media (no 
exosomes). cDNA was synthesized using the High-
Capacity RNA-to-cDNA Kit (Applied Biosystems) and 
15-50 ng cDNA was loaded per port on TaqMan Custom 
Arrays (Applied Biosystems) examining 192 genes in 
duplicates. The genes were possible target genes of the 
up-regulated GSC exosomal miRNAs or have roles in 
cell cycle, stemness, differentiation, glioma genesis, 
and neurogenesis. The arrays were run on a Viia7 Real-
Time PCR system (Applied Biosystems) according to the 
manufacturer’s instructions.
GAPDH was used as reference gene for ΔCT 
calculations, and hierarchical clustering was performed 
using Euclidean distance metric and average linkage. 
ΔΔCT-values were calculated between treatment 1) and 
3) and treatment 2) and 3) (above), to estimate a Gaussian 
distribution. From this we estimated thresholds based 
on the mean ± 1.96*(standard deviation) to determine 
differentially expressed genes.
Statistical methods
Differential expression was analyzed with limma in 
R [40], for miRNAs detected with the microarray in all 
samples included in the two groups of each comparison. 
Hierarchical clustering on miRNA expression data was 
performed on miRNAs detected in all cell line samples 
and/or all exosome samples, using Euclidean distance 
metric and average linkage.
The search for significantly over-represented motifs 
was done on miRNAs identified as overexpressed in 
exosomes compared to cells for GSCs and/or NSCs using 
Oncotarget90173www.impactjournals.com/oncotarget
the online application Improbizer (https://users.soe.ucsc.
edu/~kent/improbizer/improbizer.html). As background 
we used the miRNAs included on the arrays that were not 
identified as overexpressed.
Clustering of miRNA sequences was done with 
ClustalW, default settings, using the R package msa [41], 
and visualization was done using the R package ape [42].
Pathway analysis, Target gene prediction, 
network construction and GO analysis
Determination of targeted pathways based on Kyoto 
Encyclopedia of Genes and Genomes (KEGG pathways) 
for miRNAs was done using the DIANA TOOLS mirPath 
v3 software with the micro-T-CDS algorithm which 
predicts miRNA targets in CDS or 3’-UTR regions [43].
Based on Tarbase (validated miRNA targets) and 
microT-CDS (predicted miRNA targets) offered by the 
DIANA web tool, target networks were constructed for 
miRNAs and target genes with Cytoscape (Version 3.1.1) 
[44].
The involvement of target genes in biological 
processes was determined with the DAVID web tool using 
the GO BP_ALL settings [45, 46].
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